Last updated: March 6, 2026
What Is NDC 60429-0313?
NDC 60429-0313 refers to a specific drug listed in the National Drug Code directory. Based on available data, this NDC corresponds to Liraglutide Injection, 1.8 mg/1.5 mL marketed under the brand name Victoza by Novo Nordisk. It is used primarily for type 2 diabetes management and obesity.
Market Landscape
Current Market Size
The global diabetes therapeutics market, valued at approximately USD 55 billion in 2022, is projected to reach USD 80 billion by 2027, with GLP-1 receptor agonists like liraglutide contributing a significant share. In the United States, the GLP-1 class accounts for roughly 40% of newer antidiabetic prescriptions.
Competitive Position
Victoza holds a substantial market share among GLP-1 receptor agonists, competing with drugs such as Ozempic (semaglutide) by Novo Nordisk and Trulicity (dulaglutide) by Eli Lilly.
Key Market Drivers
- Increasing prevalence of type 2 diabetes and obesity.
- Growing acceptance of injectable GLP-1 therapies.
- Positive cardiovascular outcomes demonstrated in clinical trials, influencing prescribing patterns.
Regulatory Landscape
- Approved by the FDA for multiple indications, including glycemic control and weight management.
- Recently, expanded approvals for obesity treatment have increased market potential.
Pricing Overview
Current Price Points
The average wholesale price (AWP) for Victoza 1.8 mg/1.5 mL in the US ranges from USD 800 to USD 900 per vial, depending on the pharmacy and payer arrangements. Commercial insurers may negotiate lower prices, with actual patient out-of-pocket costs varying.
| Metric |
Value |
Source |
| Wholesale Acquisition Cost (WAC) |
USD 780 |
SSR Health (2023) |
| Average Wholesale Price (AWP) |
USD 860 |
Red Book (2023) |
| Prescription average retail cost |
USD 900 |
GoodRx data (2023) |
Price Trends
Prices for Victoza have remained relatively stable over the past three years, with minor fluctuations due to formulary negotiations and rebate strategies. The entrance of biosimilar or generic competitors remains limited due to patent protection and biologic complexity.
Future Price Projections
Factors Influencing Price Changes
- Patent Expiry:
- Patent protection for Victoza extends into 2026-2028. Loss of exclusivity could lead to price erosion.
- Biosimilar Entry:
- As of 2023, no biosimilar versions are approved in the US, although biosimilar development is underway in other markets.
- Manufacturing and R&D Costs:
- Estimated to account for approximately 10-15% of the retail price, which may influence pricing adjustments.
- Market Demand:
- The rising prevalence of diabetes and obesity sustains high demand; projected to support stable or slightly declining prices due to market saturation.
Price Projection Models
| Year |
Estimated Average Wholesale Price (USD) |
Assumptions |
| 2024 |
USD 860 |
Stable demand, no biosimilar competition, patent protection intact |
| 2025 |
USD 820 |
Slight reduction in wholesale prices, increased generic biosimilar competition in select markets |
| 2026 |
USD 750 |
Anticipated patent expiry, biosimilar entrance, price negotiations |
| 2027 |
USD 700 |
Biosimilar market penetration, price competition increases |
Potential Market Entry Impact
- Biosimilar introduction could reduce prices by 20-30%, depending on market uptake and regulatory approval.
- Payer negotiations and rebate strategies may offset retail price declines.
Market Entry Considerations
- Regulatory barriers: Biosimilar approval in the US requires demonstrating biosimilarity to Victoza.
- Patents: Licensing and patent litigations could delay biosimilar launches until after 2026.
- Market dynamics: Prescriber loyalty and clinical experience favor branded Victoza unless biosimilars demonstrate comparable efficacy and safety.
Summary
Victoza (NDC 60429-0313) holds a mature market position with stable pricing in the US, currently averaging USD 860 per vial. Price reductions are anticipated post-patent expiry around 2026, with biosimilar competition expected to exert downward pressure. Ongoing market growth driven by increasing demand for diabetes and obesity treatments supports revenue stability in the near term.
Key Takeaways
- Victoza remains a leading product in the GLP-1 receptor agonist segment with high current pricing.
- Patent expiration around 2026/patent challenges could open the market to biosimilars, driving prices down.
- US pricing is influenced by pharmacy negotiations, rebates, and payer strategies.
- Market growth continues due to rising disease prevalence, although clinical and regulatory developments could alter dynamics.
- Price projections for 2024-2027 show a gradual decline aligned with patent expiries and biosimilar entry.
FAQs
1. When will biosimilar versions of Victoza likely enter the US market?
Patent protection extends into 2026-2028. Biosimilar approval and market entry depend on patent litigation and regulatory processes, with launches often 1-2 years post-approval.
2. How does Victoza compare in price to competing GLP-1 drugs?
Victoza's retail price is roughly USD 860 per vial. Semaglutide (Ozempic/Rybelsus) has similar or slightly higher prices, while dulaglutide (Trulicity) tends to be lower, around USD 700-750.
3. What impact could regulatory changes have on pricing?
Stricter biosimilar pathways or price controls could accelerate price reductions. Conversely, new indications or market restrictions could sustain higher prices.
4. What are the main factors affecting Victoza's market share?
Clinical efficacy, prescriber loyalty, reimbursement policies, and competition from oral and injectable alternatives influence market share dynamics.
5. Is there any recent reformulation or new indication that could affect pricing or marketability?
Victoza's expanded approval for obesity treatment in 2021 increased its utilization, supporting continued demand and revenue. No recent reformulations reported.
References
[1] IMS Health. (2023). US Prescription Data.
[2] SSR Health. (2023). Wholesale Acquisition Cost Data.
[3] GoodRx. (2023). Treatment Cost Data.
[4] U.S. Food and Drug Administration. (2022). Victoza Product Label.
[5] EvaluatePharma. (2022). Global Diabetes Drugs Market Report.
